AAV Purification Platform for High Purity Gene Therapy Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current scalable AAV vector purification processes fail to adequately remove vector-related impurities, leading to immunogenicity concerns and suboptimal vector purity, which is crucial for gene therapy applications.
Innovation Solution
A modular purification platform involving a sequence of column chromatography, tangential flow filtration, and isopynic gradient ultracentrifugation is used to achieve high purity AAV vectors, efficiently separating bona fide AAV particles from empty capsids and other impurities, resulting in a product with at least 95% purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current scalable AAV vector purification processes are used, then productivity is maintained, but vector purity is insufficient and immunogenicity concerns arise
Solution Approach 1:
The purification process is divided into multiple sequential steps: chromatography step to capture AAV particles from cell lysate, followed by a density gradient ultracentrifugation step to separate full capsids from empty capsids and impurities. This segmentation allows each step to target specific impurities, achieving high vector purity (≥95%) while maintaining scalability for clinical production.
Solution Approach 2:
The chromatography step is performed as a preliminary action before density gradient ultracentrifugation to pre-concentrate and partially purify AAV particles from the complex cell lysate. This preliminary concentration reduces the volume and complexity of the sample entering the ultracentrifugation step, improving overall process efficiency and purity without requiring overly complex equipment.
2Object-affected harmful factors
If multiple purification steps are implemented to increase vector purity, then immunogenicity is reduced, but processing time and cost increase
Solution Approach 1:
The density gradient ultracentrifugation step specifically extracts and removes empty capsids and other vector-related impurities from the purified AAV preparation. By targeting and removing these specific harmful components that cause immunogenicity, the process achieves high purity (≥95%) without requiring excessive purification steps, thus minimizing processing time while effectively reducing immunogenicity risks.
3Manufacturing precision
If density gradient ultracentrifugation is used to achieve high purity, then vector-related impurities are removed, but scalability becomes challenging
Solution Approach 1:
The purification process is divided into multiple sequential steps: chromatography step to capture AAV particles from cell lysate, followed by a density gradient ultracentrifugation step to separate full capsids from empty capsids and impurities. This segmentation allows each step to target specific impurities, achieving high vector purity (≥95%) while maintaining scalability for clinical production.
Solution Approach 2:
The method optimizes ultracentrifugation parameters including gradient composition (e.g., iodixanol or sucrose gradients), centrifugal force (g-force), and duration to achieve efficient separation of full capsids from empty capsids and impurities. By carefully controlling these parameters, the process achieves high purity while maintaining scalability for clinical-grade production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances vector purity and minimizes immunogenicity, enabling effective gene delivery and reducing the risk of immune responses in human subjects, while being scalable and cost-effective for clinical applications.
Implementation Method 1
The AAV particles are purified by ion exchange column chromatography
Implementation Method 2
the eluate so generated is then added to an isopynic gradient and subjected to ultracentrifugation
Implementation Method 3
added to an isopynic gradient and subjected to ultracentrifugation, the layer containing the viral particles is harvested
Implementation Method 4
the resulting formulation filtered to remove any remaining impurities
Data Source
AI summary
Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.